Daring to be disruptive through innovation coupled with an environmental awareness.
One of the keys to Origin Peptides technology’s green credentials is the ability to perform peptide synthesis in an aqueous, one pot solution. This has several benefits.
Utilising standard amino acids is possible (FMOC and BMOC protected amino acids are not water soluble)
Removing the need for hazardous organic solvents
Lower reaction volumes and greatly improved Product Manufacturing Index (PMI ~10)*
A one pot reactions means no iterative process steps = time saving
Side chain and off target reactions caused by coupling and de-protection reagents do not occur.
*at lab scale, this may change at industrial scale
This novel and innovative process has been developed by Dr Sara ten Have.
About Dr Sara ten Have (CEO Origin Peptides)
Sara obtained her BSc in biochemistry at Macquarie University, Sydney, and then started a Master’s in human medical research at Sydney University. This was converted into a PhD after a year, given her proficiency in the lab and she completed her PhD “A Proteomic Investigation into the Pathogenesis of Endometriosis” (2D electrophoresis, and MALDI-TOF mass spectrometry, hand annotating spectra and searching manually). She moved to Otto von Guericke University in Magdeburg, Germany, for her first Post Doc, investigating the post synaptic density proteome changes in rats and mice in response to different learning reinforcement regimes, and teaching students. Additionally, she diversified into electrospray ionisation mass spectrometry and SILAC labelling for the first time.
From Germany she then took up a role at the University of Dundee in Scotland as a Proteomic consultant and technologist. For the next 9 years she worked with hundreds of scientists within the university, its associated hospital, Ninewells, and the James Hutton Institute, its agricultural research institute, as well as many international collaborations.
The breadth of experience gained by working with such a diversity of people and projects included the worlds first SILAC labelled plants (doi: 10.1371/journal.pone.0072207), mass spectrometry analysis of DNA, microRNA effects, clinical samples, drug discovery targets, protein interactions, thermal profiling, crosslinking, cellular fractionation and global proteomes.